Frontiers in Medicine (Jun 2023)
Fighting Post-COVID and ME/CFS – development of curative therapies
- Carmen Scheibenbogen,
- Judith Theresia Bellmann-Strobl,
- Judith Theresia Bellmann-Strobl,
- Judith Theresia Bellmann-Strobl,
- Cornelia Heindrich,
- Kirsten Wittke,
- Elisa Stein,
- Christiana Franke,
- Harald Prüss,
- Harald Prüss,
- Hannah Preßler,
- Marie-Luise Machule,
- Heinrich Audebert,
- Carsten Finke,
- Hanna Gwendolyn Zimmermann,
- Hanna Gwendolyn Zimmermann,
- Hanna Gwendolyn Zimmermann,
- Birgit Sawitzki,
- Birgit Sawitzki,
- Christian Meisel,
- Christian Meisel,
- Markus Toelle,
- Anne Krueger,
- Anna C. Aschenbrenner,
- Joachim L. Schultze,
- Joachim L. Schultze,
- Joachim L. Schultze,
- Marc D. Beyer,
- Marc D. Beyer,
- Markus Ralser,
- Markus Ralser,
- Michael Mülleder,
- Leif Erik Sander,
- Frank Konietschke,
- Friedemann Paul,
- Friedemann Paul,
- Friedemann Paul,
- Silvia Stojanov,
- Lisa Bruckert,
- Dennis M. Hedderich,
- Franziska Knolle,
- Gabriela Riemekasten,
- Maria J. G. T. Vehreschild,
- Oliver A. Cornely,
- Oliver A. Cornely,
- Oliver A. Cornely,
- Uta Behrends,
- Uta Behrends,
- Uta Behrends,
- Susen Burock
Affiliations
- Carmen Scheibenbogen
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Judith Theresia Bellmann-Strobl
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany
- Judith Theresia Bellmann-Strobl
- NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Judith Theresia Bellmann-Strobl
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- Cornelia Heindrich
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Kirsten Wittke
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Elisa Stein
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Christiana Franke
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Harald Prüss
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Harald Prüss
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Berlin, Germany
- Hannah Preßler
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Marie-Luise Machule
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Heinrich Audebert
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Carsten Finke
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Hanna Gwendolyn Zimmermann
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany
- Hanna Gwendolyn Zimmermann
- NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Hanna Gwendolyn Zimmermann
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- Birgit Sawitzki
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Birgit Sawitzki
- Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Center of Immunomics, Berlin, Germany
- Christian Meisel
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Christian Meisel
- Department of Immunology, Labor Berlin - Charité Vivantes GmbH, Berlin, Germany
- Markus Toelle
- Department of Nephrology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Anne Krueger
- Department of Nephrology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Anna C. Aschenbrenner
- 0Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany
- Joachim L. Schultze
- 0Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany
- Joachim L. Schultze
- 1PRECISE Platform for Single Cell Genomics and Epigenomics, DZNE and University of Bonn, Bonn, Germany
- Joachim L. Schultze
- 2Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany
- Marc D. Beyer
- 0Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany
- Marc D. Beyer
- 1PRECISE Platform for Single Cell Genomics and Epigenomics, DZNE and University of Bonn, Bonn, Germany
- Markus Ralser
- 3Institute of Biochemistry, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Markus Ralser
- 4The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Michael Mülleder
- 3Institute of Biochemistry, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Leif Erik Sander
- 5Department of Infectious Diseases and Respiratory Medicine, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Frank Konietschke
- 6Institute of Biochemistry, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Friedemann Paul
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany
- Friedemann Paul
- NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Friedemann Paul
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- Silvia Stojanov
- 7Childrens’ Hospital, School of Medicine, Technical University of Munich, Munich, Germany
- Lisa Bruckert
- 8Clinical Trial Office, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Dennis M. Hedderich
- 9Department of Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany
- Franziska Knolle
- 9Department of Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany
- Gabriela Riemekasten
- 0Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany
- Maria J. G. T. Vehreschild
- 1Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
- Oliver A. Cornely
- 2Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
- Oliver A. Cornely
- 3German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany
- Oliver A. Cornely
- 4University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- Uta Behrends
- 7Childrens’ Hospital, School of Medicine, Technical University of Munich, Munich, Germany
- Uta Behrends
- 5German Center for Infection Research (DZIF), Berlin, Germany
- Uta Behrends
- 6AGV Research Unit Gene Vectors, Helmholtz Center Munich (HMGU), Munich, Germany
- Susen Burock
- 8Clinical Trial Office, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- DOI
- https://doi.org/10.3389/fmed.2023.1194754
- Journal volume & issue
-
Vol. 10
Abstract
The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.
Keywords
